Tagged with Novartis,

Austria Like a family recipe that has been refined and perfected over countless generations, Austria has developed a reputation as the quintessential clinical trials destination; a perfect combination of world-class academia, willing volunteers and educated medical personnel balanced against a backdrop of economic stability. “Austria should be proud of the abundance…

Austria Ard van der Meij, country president of Novartis Group Austria, the nation’s leading pharmaceutical company, discusses the advantages in Austria for innovative companies and the steps required to bolster the generics and biosimilars market share within the Austrian market to create a sustainable healthcare ecosystem for the long-term. Furthermore, he…

Hong Kong Novartis Hong Kong general manager Dorine Leung and oncology head Sian Ng discuss the company’s restructuring, dividing the oncology business unit from the pharmaceutical division. In addition, they share their insights on what makes Hong Kong a destination for world-class clinical trials. Novartis recently underwent a major restructuring with the…

Indonesia Milan Paleja, country president and general manager of Novartis Indonesia, discusses his main priorities since assuming his current position and the organization’s business expansion strategy, based on enhancing patient access to innovative medicines in both the public and private sectors. Mr. Paleja, you were appointed as country president and general…

Greece In terms of value, global giants Pfizer, Novartis and Sanofi lead the way in Greece. Click here to see more facts and figures from Greece

Taiwan Mike Exton, Managing Director at Novartis Taiwan, describes the affiliate’s plans to increase collaboration with the government in order to provide Taiwanese patients with a greater access to innovative, life-changing products, while highlighting Novartis’ world-class innovation in many critical therapeutic areas, such as heart failure, as well as the skilled…

Healthcare PharmaBoardroom has spoken to a wide variety of actors at the cutting edge of healthcare digitalization over the past 12 months. Hot topics have included the healthcare industry’s slow reaction to digital trends, new modes of hospital care, homecare, and digitalization’s potential to expand access in remote and underdeveloped areas.…

Singapore Christopher Snook discusses his dual role as Head of Group Country Management as well as Country President for Singapore, highlighting the importance of adhering to in-house as well as country-specific regulatory frameworks and the continued importance of Singapore to the global group.   We will continue to see Singapore in…

Switzerland Frederic Bengold, MD of Servier Switzerland, on the affiliate’s main growth drivers, an exciting collaboration with Novartis on heart failure medication, and the intricacies of market access in Switzerland. Could you please start by introducing Servier’s Swiss affiliate? We enjoy a longstanding presence and reputation in Switzerland. The local affiliate…

Philippines Cheryl Maley, General Manager of Novartis Philippines, discusses the company’s operations in the country, their growing portfolio of products as well as their impressive focus on research and development in the Philippines. She also discusses some of her key objectives and goals for her first country leadership role. As an…

Philippines Bakhuti Shengelia, Director Healthcare Systems of Novartis International AG, expands on Novartis’ initiatives to increase access to healthcare in emerging markets as well as the importance of transitioning towards value-based healthcare systems to improve healthcare outcomes. He also discusses how emerging markets are able leverage the fact they have more…

Luxembourg Novartis’ newest Head for the Grand-Duchy of Luxembourg provides a fascinating insight into the Luxembourg market and reveals how this small nation has found itself in pole position for future pharmaceutical innovation. After over a decade with GSK, you joined Novartis one and half years ago. What made you join…